Compare Stocks → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATRANASDAQ:DBVTNASDAQ:EIGRNASDAQ:HUMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$0.70+6.1%$0.72$0.20▼$3.02$83.24M0.692.75 million shs856,377 shsDBVTDBV Technologies$0.66-2.9%$0.79$0.65▼$2.37$127.29M0.7550,041 shs43,412 shsEIGREiger BioPharmaceuticals$1.73-9.2%$5.04$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsHUMAHumacyte$3.70$3.53$1.96▼$5.60$440.61M1.461.11 million shs2.62 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+5.51%+2.77%0.00%+16.04%-77.06%DBVTDBV Technologies-3.18%-5.12%-17.11%-25.00%-57.96%EIGREiger BioPharmaceuticals0.00%0.00%-70.05%-74.06%-94.52%HUMAHumacyte0.00%+28.92%+11.78%+27.15%+11.78%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.8623 of 5 stars3.02.00.04.72.62.50.6DBVTDBV Technologies1.4228 of 5 stars3.21.00.00.00.03.31.3EIGREiger BioPharmaceuticals4.0781 of 5 stars3.55.00.04.20.61.70.6HUMAHumacyte2.2766 of 5 stars3.42.00.00.02.82.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics2.00Hold$28.003,914.91% UpsideDBVTDBV Technologies2.33Hold$5.00657.58% UpsideEIGREiger BioPharmaceuticals3.00Buy$120.006,856.52% UpsideHUMAHumacyte2.75Moderate Buy$8.00116.22% UpsideCurrent Analyst RatingsLatest DBVT, ATRA, HUMA, and EIGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024HUMAHumacyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.003/26/2024HUMAHumacytePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.003/25/2024HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$8.57M9.71N/AN/A($0.97) per share-0.72DBVTDBV Technologies$15.73M8.09N/AN/A$0.73 per share0.90EIGREiger BioPharmaceuticals$15.77M0.16N/AN/A$37.68 per share0.05HUMAHumacyte$1.57M280.64N/AN/A$0.13 per share28.46Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)DBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)EIGREiger BioPharmaceuticals-$96.78M-$59.16N/A∞N/A-590.80%-332.49%-99.77%5/9/2024 (Estimated)HUMAHumacyte-$110.78M-$1.07N/AN/AN/AN/A-199.62%-61.45%5/10/2024 (Estimated)Latest DBVT, ATRA, HUMA, and EIGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/22/2024Q4 2023HUMAHumacyte-$0.25-$0.24+$0.01-$0.24$0.10 millionN/A 3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.720.65DBVTDBV TechnologiesN/A4.264.26EIGREiger BioPharmaceuticalsN/A3.313.24HUMAHumacyte1.204.524.52OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%DBVTDBV Technologies71.74%EIGREiger BioPharmaceuticals62.46%HUMAHumacyte44.71%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.50%DBVTDBV Technologies0.60%EIGREiger BioPharmaceuticals4.22%HUMAHumacyte23.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableDBVTDBV Technologies104192.87 million191.71 millionOptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableHUMAHumacyte183119.08 million91.58 millionOptionableDBVT, ATRA, HUMA, and EIGR HeadlinesSourceHeadlineA U.S. Senator Just Bought this Tiny Stock – It’s Up 15% Todaymsn.com - April 20 at 2:59 PMU.S. Senator trading alert: This stock surged 40% within 4 days of disclosurefinbold.com - April 19 at 2:16 PMHere’s why the Humacyte (HUMA) stock price is pumpinginvezz.com - April 19 at 2:04 PMThis US politician just made a really suspicious tradefinbold.com - April 19 at 4:24 AMA U.S. Senator Just Bought this Tiny Stock - It's Up 15% Todaymsn.com - April 18 at 7:56 PMAlly Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursdaybenzinga.com - April 18 at 2:55 PMFormer HHS secretaries: Congress should adopt site-neutral payments for health carestatnews.com - April 18 at 2:55 PMTuberville’s Trading Raises Questions: Senator Sells Put Options, Invests in Small Biotech Tied to Ukraine-Russia Conflictmsn.com - April 18 at 2:55 PMShort Interest in Humacyte, Inc. (NASDAQ:HUMA) Expands By 5.3%americanbankingnews.com - April 18 at 4:28 AMSolventum appoints Shirley Edwards to board of directorsmedtechdive.com - April 17 at 11:14 PMU.S. Senator Tommy Tuberville Just Reported a Purchase of $HUMA stockca.investing.com - April 17 at 11:14 PMHumacyte, Inc. (HUMA) Interactive Stock Chart - Yahoo Financefinance.yahoo.com - April 15 at 11:26 PMOppenheimer Keeps Their Buy Rating on Humacyte (HUMA)markets.businessinsider.com - April 8 at 4:08 PMResearch Analysts Set Expectations for Humacyte, Inc.'s FY2024 Earnings (NASDAQ:HUMA)marketbeat.com - April 4 at 9:14 AMHumacyte's (HUMA) Overweight Rating Reiterated at Cantor Fitzgeraldmarketbeat.com - April 1 at 9:10 AMShort Interest in Humacyte, Inc. (NASDAQ:HUMA) Declines By 36.5%marketbeat.com - March 29 at 10:48 AMHumacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024globenewswire.com - March 26 at 4:05 PMHumacyte's (HUMA) "Buy" Rating Reiterated at Benchmarkmarketbeat.com - March 25 at 12:21 PMHumacyte’s Strong Outlook: Buy Rating Affirmed Amid Advancements and Market Opportunitymarkets.businessinsider.com - March 23 at 6:39 PMQ4 2023 Humacyte Inc Earnings Callfinance.yahoo.com - March 23 at 8:42 AMHumacyte (NASDAQ:HUMA) Posts Earnings Resultsmarketbeat.com - March 23 at 8:26 AMBuy Rating for Humacyte: Anticipated FDA Approval and Strong Financials Signal Growth Potentialmarkets.businessinsider.com - March 22 at 10:41 PMHUMA Stock Earnings: Humacyte Meets EPS for Q4 2023investorplace.com - March 22 at 11:53 AMHumacyte GAAP EPS of -$0.24 in-linemsn.com - March 22 at 10:12 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideCan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsAtara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Eiger BioPharmaceuticalsNASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.HumacyteNASDAQ:HUMAHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.